Kidney transplants recipients received 2 doses of ChAdOx1 nCoV-19 and 1 dose of BNT162b2 and receiving MPA and CNI Kidney transplants COVID SARS-CoV-2 Vaccine
Conditions
Interventions
Switching immunosuppressive agents from MPA and CNI to low dose prograf (C0 2-4 ng/mL) and mTOR inhibitor 2 weeks before and after BNT162b2.,Remain using MPA and CNI throughout the study
Experimental Drug,Active Comparator Drug
Switching arm,Continue previous regimen
Sponsors
Division of nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 2. Kidney transplant > 6 months 3. Receiving MPA and CNI 4. Received 2 doses of ChAdOx1 nCoV-19 and 1 dose of BNT162b2 for 3-5 months
Exclusion criteria
Exclusion criteria: 1. History of severe allergy from BNT162b2 2. Rejection within 6 months 3. High risk for rejection : ABO incompatible, multiorgan transplantation, previous transplantation, recent panel reactive antibody (PRA) > 20% or donor specific antibody (DSA) positive 4. Pregnancy or lactation 5. Advanced stage cancer 6. AIDs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anti-SARS-CoV-2 antibodies 1 month ELISA | — |
Secondary
| Measure | Time frame |
|---|---|
| N/A N/A N/A | — |
Countries
Thailand
Contacts
Public ContactAthiphat Banjongjit
Division of nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University
Outcome results
None listed